Please sign in with your existing account details.
Register to access exclusive content, sign up to receive our updates and personalise your experience on brownejacobson.com.
Privacy statement - Terms and conditions
Forgotten your password?
You have exceeded the maximum number of login attempts for this email address and your account has been locked. An email has been sent to member of Browne Jacobson's web team and some one will be contacting you over the next two working days with details of how to change your password.
Are you sure you want to remove this item from you pinned content?
Six months after the Upper Tribunal ruling that the Charity Commission’s guidance on the public benefit of private schools was flawed, the Commission has begun a consultation on its new draft guidance.
Originally the Independent Schools Council (“ISC”) argued that the Charity Commission’s original guidance focused too heavily on the benefit of financial scholarships for poorer students and devalued the sharing of facilities, loaning of staff and exchange of students with state schools. In return the Commission argued that “minimal and tokenistic” activities would not be sufficient to pass the public benefit test and that charities which failed the test risked losing their charitable tax benefits.
The revised guidance acknowledges both arguments and provides examples of acceptable activities which include providing bursaries and the sharing of facilities.
The consultation on the draft guidance runs until the end of September and will no doubt be scrutinised by the ISC and its members during that time and afterwards.
With the Prime Ministers announcement that he intends for Step 4 to begin on 19 July, this will also bring an end to the restrictions currently in place on education settings.
View blog
The issue of Female Genital Mutilation Protection Orders and the importance of education providers to act promptly.
Our top tips for supporting transgender and non-binary pupils.
On 4 June, the Medicines and Healthcare products Regulatory Agency (MHRA) approved the use of the Pfizer/BioNTech Covid-19 vaccine for 12- to 15-year-olds.
Associate
Select which mailings you would like to receive from us.
Sign up